Holen Sie sich die Stockscreener-App
0.7743
0.83%
0.0064
Ocugen Inc Aktie (OCGN) Neueste Nachrichten
Ocugen Inc. stock rises Friday, still underperforms market - MarketWatch
Ocugen to Present at Oppenheimer Movers in Rare Disease Summit - MSN
Ocugen’s Gene Therapy Trial for Dry AMD Advances - MyChesCo
Ocugen Inc. stock rises Thursday, outperforms market - MarketWatch
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen
Ocugen's Eye Treatment Shows Promising Safety Data in Phase 1/2 Trial for Macular Degeneration - StockTitan
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc. stock falls Monday, underperforms market - MarketWatch
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Oppenheimer Movers in Rare Disease Summit - Ocugen
Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit - Ocugen
Ocugen CEO to Showcase Breakthrough Gene Therapy Programs at Oppenheimer Rare Disease Summit - StockTitan
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference - Ocugen
Ocugen, Inc. to Present at NobleCon20 Emerging Growth Equity Conference - MSN
ocugen director Fernandes buys $9,095 in common stock - Investing.com
ocugen director Fernandes buys $9,095 in common stock By Investing.com - Investing.com Australia
Ocugen CEO to Present at NobleCon20 – Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference - Ocugen
Ocugen CEO to Present Clinical Program Updates at NobleCon20 Conference | OCGN Stock News - StockTitan
Ocugen director Kirsten Castillo buys $22,847 in stock - Investing.com India
Ocugen director Kirsten Castillo buys $22,847 in stock By Investing.com - Investing.com Australia
Ocugen Reports Promising Results from OCU410 ArMaDa Trial for Geographic Atrophy - MSN
Ocugen Secures EMA Orphan Designation for OCU410ST, Advancing Stargardt Disease Treatment - MSN
Ocugen Announces European Medicines Agency Grants Orphan - GlobeNewswire
Ocugen reports positive data for OCU400, OCU410 - MSN
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen announces EMA granted orphan medicinal product designation for OCU410ST - TipRanks
Ocugen Advances Gene Therapy and Financial Strategies in Q3 2024 - MSN
Ocugen Announces European Medicines Agency Grants Orphan Medicinal Product Designation for Modifier Gene Therapy Candidate OCU410ST for Treatment of ABCA4-Associated Retinopathies including Stargardt Disease - The Manila Times
Ocugen's Eye Disease Drug Shows 84% Lesion Reduction, Receives EMA Orphan Status | OCGN Stock News - StockTitan
Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy - Ophthalmology Times
Ocugen announces preliminary efficacy, safety data from Phase 1/2 OCU410 trial - TipRanks
Ocugen Announces Compelling Preliminary Data for OCU410—a Single Dose Novel Modifier Gene Therapy to Treat Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration - Ocugen
Ocugen Announces Compelling Preliminary Data for OCU410—a - GlobeNewswire
Ocugen's Eye Treatment Shows 21% Disease Slowdown in Phase 1 Trial Data | OCGN Stock News - StockTitan
OCGN Stock: Can New Leadership Save This Biotech Company? - TipRanks
Ocugen Inc. stock falls Friday, underperforms market - MarketWatch
Ocugen Appoints Ramesh Ramachandran as Financial Officer - TipRanks
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):